ZURICH: US biotech firm Regeneron and its Swiss partner Roche unveiled promising clinical trial results on Monday indicating that an antibody treatment used to treat Covid-19 patients also helps prevent infections. The results of the Phase 3 trial showed that the combination of the antibodies casirivimab and imdevimab dramatically reduced the risk of symptomatic infection among people living with Covid-19 patients, Roche said in a statement.
A representational image shows a handcuffed suspect standing behind bars. — APP/FileMOSCOW: A Russian military court...
Activist Kianoosh Sanjari can be seen beside mic. — AFP/FilePARIS: Human rights campaigners on Thursday paid...
